GILEAD SCIENCES, INC. - 13 Feb 2026 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Reporting relationship: 10%+ Owner
Issuer ticker: XLO
Reported as of: 13 Feb 2026
Net transaction value: +$1,999,991
SEC form: 4
Accepted by SEC: 17 Feb 2026, 17:31:38 UTC
Prior SEC filing: 01 Dec 2025
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson

Key filing fact

GILEAD SCIENCES, INC. filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 17 Feb 2026.

Key facts

This page summarizes GILEAD SCIENCES, INC.'s Form 4 filing for Xilio Therapeutics, Inc. (XLO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2026, 17:31.

Change

Previous filing in this sequence was filed on 01 Dec 2025.
Current net transaction value: +$1,999,991.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000882095 Primary reporting owner

GILEAD SCIENCES, INC.

Relationship: 10%+ Owner
Address: 333 LAKESIDE DRIVE, FOSTER CITY
Signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Signature date: 17 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XLO transaction Derivative

Prefunded Warrants (right to buy)

Purchase

Transaction value: $1,999,991
Shares: +3,739,000
Change %: +10%
Price: $0.5349
Shares after: 40,384,266
Date: 13 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,739,000
Exercise price: $0.000100
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date. A holder of Prefunded Warrants may not exercise such warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer.